NIACOR

Post-LOE

niacin

Molecular Devices

ANDAORALTABLET

Approved

May 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

NIACOR (niacin) by Molecular Devices is clinical pharmacology the role of low-density lipoprotein (ldl) cholesterol in atherogenesis is supported by pathological observations, clinical studies, and many animal experiments. Approved for primary hypercholesterolemia (types iia, iib), the response to a diet restricted in saturated fat and 2 more indications. First approved in 2000.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY The role of low-density lipoprotein (LDL) cholesterol in atherogenesis is supported by pathological observations, clinical studies, and many animal experiments. Observational epidemiological studies have clearly established that high total or LDL cholesterol and low…

Worked on NIACOR at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT06868771N/ARecruiting

Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR

Started Jul 2022

164 enrolled

Xerosis Cutis

NCT01583647Phase 1Terminated

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)

Started Jun 2012

10 enrolled

Hypercholesterolemia, FamilialHeterozygous Familial Hypercholesterolemia

NCT01426438Phase 2Completed

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

Started Nov 2011

99 enrolled

HIV-1 Infection

NCT01308203Phase 4Terminated

Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease

Started Oct 2011

32 enrolled

Coronary Artery DiseaseDyslipidemias

NCT01414166Phase 3Terminated

Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

Started Sep 2011

244 enrolled

Dyslipidemia

NIACOR

Mechanism of Action

Indications (5)

Clinical Trials (20)